Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases

Crit Rev Oncol Hematol. 2019 Jun:138:190-206. doi: 10.1016/j.critrevonc.2019.03.017. Epub 2019 Apr 3.

Abstract

The presence of an epidermal growth factor receptor (EGFR) mutation is associated with higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); however, patients with synchronous brain metastases at diagnosis have generally been excluded from clinical trials. As there is limited clinical evidence for managing this patient population, a multidisciplinary group of Spanish medical and radiation oncologists, and neuro-oncologist with expertise treating brain metastases in lung cancer patients met with the aim of reaching and developing an expert opinion consensus on the management of patients with EGFR mutated NSCLC with brain metastases. This consensus contains 26 recommendations and 20 conclusion statements across 21 questions in 7 areas, as well as a first-line treatment algorithm.

Keywords: Brain metastases; Consensus; Diagnosis; EGFR mutation; Management; NSCLC; Recommendation; Treatment.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Brain Neoplasms / genetics
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / secondary*
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Consensus
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Incidence
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy*
  • Mutation

Substances

  • EGFR protein, human
  • ErbB Receptors